Hoth Therapeutics, Inc.HOTH
時価総額
$1418.7万
PER
バイオ医薬品の新興企業。HT-005などのカンナビノイド治療薬や前臨床・臨床候補を展開。2017年5月設立、2020年5月にZylö株120,000株取得、2021年12月にHT-005を再許諾。米国中心に展開。
| 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net loss | - | - | - | - | - | - | -8,188,300 |
| Stock-based compensation | 143,053 | 2 | 737,746 | - | 620,798 | 216,428 | 804,277 |
| Unrealized loss on marketable securities | - | 3,664 | 50,553 | -176,974 | 119,870 | -209,320 | - |
| Change in fair value of investment in joint venture | - | - | - | - | - | - | -581 |
| Prepaid expenses | 12,356 | 97,716 | -20,236 | 5,420 | -3,847 | 47,300 | -252,178 |
| Accounts payable and accrued expenses | - | - | - | - | - | - | 153,013 |
| NET CASH USED IN OPERATING ACTIVITIES | -2,102,626 | -4,947,215 | -6,133,198 | -12,090,129 | -9,297,854 | -8,447,094 | -6,978,251 |
| Proceeds from issuance of common stock, common stock warrants and prefunded warrants, net of offering costs | - | 6 | - | - | - | - | 1 |
| Proceeds from exercise of warrants, net of issuance costs | - | - | - | - | - | 2,355 | 4 |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 1 | 7 | 9 | 18 | 6 | 11 | 5 |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | - | - | - | - | - | 3 | -2,235,232 |
| Effect of exchange rate changes on cash and cash equivalents | - | - | - | - | -9,593 | -6,518 | -18,197 |
| ROU assets obtained in exchange for lease liability | - | - | - | - | - | 59,698 | - |